Derived nearly 40 years ago, the NCI-H460 cell line has a
few unique characteristics that have made it one of the principal cell lines
used in lung cancer research. NCI-H460 cells do not have significant damage to
DNA, and they express normal amounts of p53 mRNA, making their proliferation
somewhat of a mystery and a path towards discovering complex cell proliferation
and tumorigenesis pathways. In terms of gene therapies to combat late-stage
lung cancer, transfection
reagents that are not cytotoxic can show how the large-cell carcinoma that
is the NCI-H460 cell line responds to changes in its genome, possibly
discovering novel manners of curing lung cancer even after late diagnosis.
In 1982 the NCI-H460 cell line was discovered using the cells of a male patient with large cell lung carcinoma. These cells exhibit epithelial cellular morphology, are tumorigenic and express p53 mRNA similar to normal lung cells. This tumorigenic cell line is particularly unique in that it expresses no different structural DNA abnormalities, and its modal chromosome number of 57 makes it ideal for lung cancer research. The NCI-H460 cell line is typically used in molecular and biomedical lung cancer research. Altogen Biosystems manufactures a high efficiency lipid-based transfection reagent to facilitate these studies. Transfection Reagent for NCI-H460 Cells (Lung Carcinoma Cells, HTB-177)
Comments
Post a Comment